Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00316017 · ClinicalTrials.gov registry record · Phase 3
Hypertonic Resuscitation Following Traumatic Injury
A Phase 3 study, sponsored by University of Washington.
- Terminated
- Registry status
- Phase 3
- Development phase
- 895
- Enrollment target
NCT00316017: Clinical Trial Phase 3 study, sponsored by University of Washington.
NCT00316017 is a Phase 3 study that was terminated before completion, run by University of Washington. The registered enrollment target is 895 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (16% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00316017, a Phase 3 study, was terminated before completion, sponsored by University of Washington.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 895 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if hypertonic saline with and without dextran can improve overall survival in victims of trauma with shock. Injury and lost blood from trauma can cause your body to be in shock (low blood pressure related to blood loss). This decreased blood flow can lead to organ damage. In order to restore the blood pressure and blood flow, the medics give fluids into the patients' veins as soon as possible. This is called "resuscitation." The resuscitation fluid most commonly used is "isotonic" or one that is the same concentration as the blood. The investigators are trying to determine if infusing a "hypertonic" fluid (or one more concentrated than the blood) can increase the blood pressure and restore blood flow more efficiently. The hypertonic fluids the investigators are using are called hypertonic saline with dextran (HSD) and hypertonic saline (no dextran). Hypertonic saline is a salt solution that is slightly more concentrated than your blood. Dextran is a sugar solution.
Primary Outcome
The day of episode is counted as "Day 0". So for measures using a 28 day period, the maximum value is 29 (i.e. days 0 through 28).
Interventions
- DRUG 0.9% normal saline
- DRUG 7.5% hypertonic saline/6% Dextran-70 (HSD)
- DRUG 7.5% hypertonic saline (HS)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 895 participants |
| Start Date | 2006-05 |
| Est. Completion | 2009-08 |
| Phase | Phase 3 |
Why NCT00316017 stopped before completion
NCT00316017 is an interventional study that assigns participants to a tested intervention. The registered 895 participants enrollment target is mid-sized for trials with a published cap, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (16% higher).
The record links to 0 conditions, and to 3 interventions - of which 0.9% normal saline is the first listed.
NCT00316017 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00316017 about?
NCT00316017 is a clinical study titled "Hypertonic Resuscitation Following Traumatic Injury". The purpose of this study is to determine if hypertonic saline with and without dextran can improve overall survival in victims of trauma with shock. Injury and lost blood from trauma can cause your body to be in shock (low blood pressure related to blood loss). This decreased blood flow can lead t...
What is the current status of trial NCT00316017?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 895 participants. The study started on 2006-05. Estimated completion is 2009-08.
What interventions are being tested in trial NCT00316017?
The interventions under investigation include: 0.9% normal saline (DRUG), 7.5% hypertonic saline/6% Dextran-70 (HSD) (DRUG), 7.5% hypertonic saline (HS) (DRUG).
Who is sponsoring clinical trial NCT00316017?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00316017's enrollment target sits among peer trials
895 361st of 2000 higher than 1,638 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04862663 · 895 participants · Phase 3
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
- NCT05855200 · 892 participants · Phase 3
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
- NCT02352116 · 900 participants · NA
Evaluation of Post-PACU Pain Management in Pediatric Surgery
- NCT02414347 · 900 participants
F 18 T807 Tau PET Imaging of Alzheimer's Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia